ATE422884T1 - Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie - Google Patents

Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie

Info

Publication number
ATE422884T1
ATE422884T1 AT03737984T AT03737984T ATE422884T1 AT E422884 T1 ATE422884 T1 AT E422884T1 AT 03737984 T AT03737984 T AT 03737984T AT 03737984 T AT03737984 T AT 03737984T AT E422884 T1 ATE422884 T1 AT E422884T1
Authority
AT
Austria
Prior art keywords
hyperlipidemia
treatment
substituted
methods
cyanopyrrolidines
Prior art date
Application number
AT03737984T
Other languages
German (de)
English (en)
Inventor
David Holmes
Thomas Hughes
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE422884T1 publication Critical patent/ATE422884T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03737984T 2002-06-03 2003-06-02 Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie ATE422884T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38522002P 2002-06-03 2002-06-03

Publications (1)

Publication Number Publication Date
ATE422884T1 true ATE422884T1 (de) 2009-03-15

Family

ID=29712145

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737984T ATE422884T1 (de) 2002-06-03 2003-06-02 Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie

Country Status (25)

Country Link
US (2) US20050176806A1 (enExample)
EP (1) EP1513519B1 (enExample)
JP (2) JP2005532338A (enExample)
KR (1) KR20050012771A (enExample)
CN (2) CN100402026C (enExample)
AT (1) ATE422884T1 (enExample)
AU (2) AU2003245903B2 (enExample)
BR (1) BR0311535A (enExample)
CA (1) CA2487297C (enExample)
CY (1) CY1112800T1 (enExample)
DE (1) DE60326232D1 (enExample)
DK (1) DK1513519T3 (enExample)
EC (1) ECSP045469A (enExample)
ES (1) ES2321600T3 (enExample)
IL (1) IL165181A (enExample)
MX (1) MXPA04012149A (enExample)
NO (1) NO333585B1 (enExample)
NZ (1) NZ536832A (enExample)
PL (1) PL210408B1 (enExample)
PT (1) PT1513519E (enExample)
RU (1) RU2362555C2 (enExample)
SG (1) SG154333A1 (enExample)
SI (1) SI1513519T1 (enExample)
WO (1) WO2003101448A1 (enExample)
ZA (1) ZA200409136B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532338A (ja) * 2002-06-03 2005-10-27 ノバルティス アクチエンゲゼルシャフト 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
ES2684325T5 (es) * 2004-01-20 2024-06-10 Novartis Ag Formulación y proceso de compresión directa
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
CN113811359A (zh) * 2019-03-22 2021-12-17 拉什大学医学中心 用于溶酶体贮积症的经鼻基因递送和口服肉桂酸、油酰胺或吉非贝齐的组合

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
TW222626B (enExample) * 1991-07-22 1994-04-21 Pfizer
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6803357B1 (en) * 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
JP4232332B2 (ja) * 1999-11-10 2009-03-04 末藏 岩田 タンク付電動床磨機用ブラシ台
ES2487897T3 (es) * 2000-01-21 2014-08-25 Novartis Ag Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
CA2464995A1 (en) * 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP2005532338A (ja) * 2002-06-03 2005-10-27 ノバルティス アクチエンゲゼルシャフト 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
KR101368525B1 (ko) * 2005-09-20 2014-03-06 노파르티스 아게 저혈당 증상을 저하시키기 위한 dpp-ⅳ 억제제의 용도

Also Published As

Publication number Publication date
AU2006246483A1 (en) 2006-12-21
PL374016A1 (en) 2005-09-19
CN101273987A (zh) 2008-10-01
ECSP045469A (es) 2005-01-28
NZ536832A (en) 2006-11-30
IL165181A (en) 2010-06-16
JP2005532338A (ja) 2005-10-27
IL165181A0 (en) 2005-12-18
NO20045452L (no) 2005-03-01
EP1513519B1 (en) 2009-02-18
HK1074794A1 (en) 2005-11-25
AU2006246483B2 (en) 2010-06-24
PL210408B1 (pl) 2012-01-31
CN1658867A (zh) 2005-08-24
AU2006246483B9 (en) 2010-08-12
CY1112800T1 (el) 2016-02-10
DK1513519T3 (da) 2009-06-02
ES2321600T3 (es) 2009-06-09
CN100402026C (zh) 2008-07-16
MXPA04012149A (es) 2005-04-19
AU2003245903A1 (en) 2003-12-19
RU2004139029A (ru) 2005-08-27
SI1513519T1 (sl) 2009-06-30
NO333585B1 (no) 2013-07-15
US20120014907A1 (en) 2012-01-19
SG154333A1 (en) 2009-08-28
AU2003245903B2 (en) 2006-11-30
DE60326232D1 (de) 2009-04-02
CA2487297A1 (en) 2003-12-11
US20050176806A1 (en) 2005-08-11
CA2487297C (en) 2011-08-09
RU2362555C2 (ru) 2009-07-27
JP2010155866A (ja) 2010-07-15
ZA200409136B (en) 2005-07-27
BR0311535A (pt) 2005-02-22
PT1513519E (pt) 2009-05-06
KR20050012771A (ko) 2005-02-02
WO2003101448A1 (en) 2003-12-11
EP1513519A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CY1112800T1 (el) Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
PE58699A1 (es) Derivados de acido arilsulfonil hidroxamico
HRP20041137B1 (hr) Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi
ATE421322T1 (de) Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
ATE240328T1 (de) Substituierte azaoxindolederivate
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
EP1794120A4 (en) peptidase
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
ATE438617T1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
TW200716597A (en) Novel piperidine-substituted indoles
MY143862A (en) Piperidine-substituted indoles-or heteroderivatives thereof
EP1325918A4 (en) INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE
DE69904025D1 (de) Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
ATE355287T1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
DK0706796T3 (da) Dopamingenoptagelsesinhibitorer til behandling af parkinsonisme
SE9902147L (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1513519

Country of ref document: EP